Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies

Value Health. 2019 Aug;22(8):970-971. doi: 10.1016/j.jval.2018.12.013. Epub 2019 May 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Drug Costs
  • Genetic Therapy
  • Humans
  • Retinal Diseases*
  • United States
  • United States Food and Drug Administration